drugset / Trial / NCT03652233
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1
Withdrawn
Vanderbilt-Ingram Cancer Center
Boehringer Ingelheim · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/Ib trial will assess the dose, safety and side effects of the combination of the cancer drugs afatinib (GILOTRIF®) and nivolumab (OPDIVO®) and to assess the anti-cancer effects of this combination of drugs when used to treat patients with advanced head and neck cancers that did not respond to previous treatments.
Timeline
- Start
- 2018-11-02
- Primary completion
- 2021-11
- Completion
- 2022-11
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |